Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure

AIMS: Heart failure (HF) and type 2 diabetes (T2D), common co‐morbidities, translate into worse patient prognoses and higher direct costs than for either condition alone. Empagliflozin has been shown to markedly reduce cardiovascular (CV) deaths and HF hospitalizations (HHF) in HF patients with T2D....

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :ESC Heart Fail
Главные авторы: Reifsnider, Odette S., Kansal, Anuraag R., Franke, Jennifer, Lee, Joseph, George, Jyothis T., Brueckmann, Martina, Kaspers, Stefan, Brand, Sarah B., Ustyugova, Anastasia, Linden, Stephan, Stargardter, Matthew, Hau, Nikco
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2020
Предметы:
Original Research Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7754962/
https://ncbi.nlm.nih.gov/pubmed/32909680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12985
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы